Navigation Links
Research: Dosage of Morphine for ill Newborns Still too Imprecise
Date:12/22/2009

LEIDEN, The Netherlands, December 22 /PRNewswire/ -- Dosage recommendations for newborns being cared for in an intensive care unit will in the future most likely be based on more individual characteristics than just body weight. This is the result of a study conducted by the Dutch Top Institute Pharma in which Leiden University (Prof M. Danhof) and the Rotterdam Erasmus Medical Centre/Sophia Children's Hospital (Prof D. Tibboel) are represented.

Catherijne Knibbe, clinical pharmacologist from the Leiden/Amsterdam Centre for Drug Research of Leiden University: "For morphine the preliminary study results show that for example a quarter of the current standard dose is sufficient for premature babies. The Erasmus MC/Sophia Children's Hospital had already noted in practice that some babies experienced withdrawal symptoms after long-term treatment with morphine. Now research has shown that the required amount of morphine can vary greatly per baby."

The dosage for children is often adjusted solely according to body weight, but that now seems to be insufficient. Knibbe said about the common used sedative midazolam: "A healthy child may be prescribed far more midazolam than for example a child with the same body weight lying in the intensive care unit with a severe infection. This study provides guidelines for arriving at a dosage recommendation that is adjusted better to the individual child. This is an enormous advance." According to Knibbe, this information is very important for doctors, as well as for pharmaceutical companies, which have been required for the past two years to conform to stricter European legislation for medicinal products for children.

This study required an intensive collaboration between clinical pharmacologists and pediatricians from the various institutes using modern methods like PK/PD modeling. Complex computer models can determine the correct dosage from small quantities of blood, taking into account the child's specific characteristics. Knibbe: "We know too little about the effects of medicinal products on children, especially newborns. Although we actually need more information than for adults. Children change so rapidly. In the first year of life the child changes each week, and responds differently and breaks down medicinal products differently. I think that these study results will mean that in some cases children will receive less medication, and thus fewer adverse effects will develop, while the child will still be treated well. I consider that a major benefit: for doctors, but most especially for the children and their parents."

The Top Institute Pharma is a collaboration between universities, university medical centers and pharmaceutical companies. This intensive collaboration accelerates research into new medicinal products and a better use of medication. The Dutch Ministry of Public Health, Welfare and Sport supports the Top Institute Pharma.

For more information, please contact Albert Reinders: +31-6-53184737.

SOURCE Top Institute Pharma


'/>"/>
SOURCE Top Institute Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ
2. Important Step Forward in Osteoarthritis Research: Bioactive Collagen Peptides Stimulate the Regeneration of Cartilage Tissue
3. Setting the Benchmark for Winery Tasting Room Research: An Emerging Region Gets a Global Perspective
4. New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague
5. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
6. U-M research: New plastic is strong as steel, transparent
7. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
8. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
9. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
10. ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets
11. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
Breaking Biology Technology:
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):